In 1996, MDS Pharma Services pioneered the first Contract Research Organization (CRO) in China, marking a pivotal shift in advancing clinical trials for new drugs in the country. This transformation was fueled by changes in the US drug research from the 1970s to 1980s. Stringent regulations from the U.S. FDA necessitated increased time and resources for R&D, sparking intense competition among pharmaceutical companies. In response, CROs emerged as external partners, enabling companies to swiftly assemble highly specialized teams. This approach proved effective, significantly reducing drug R&D cycles and overall costs, gaining favor among major industry players, and fundamentally shaping the competitive pharmaceutical landscape.
Fast forward to 2023, after eight years of development, Sanyou Biopharmaceuticals have evolved and established an end-to-end complete supply chain for drug R&D. In addition to CRO services, we expanded into Contract Development Organization (CDO), Cooperative Project Organization (CPO), and Core Reagent Solution (CRS). These additions, provide specialized and efficient support for the development and production of biopharmaceuticals, promoting growth in the field. |
|
|
| Sanyou's 4C business model is instrumental in shaping the landscape of biopharmaceuticals. Using a metaphorical tree, the CDO represents flower blossoms, symbolising the progression of drug development. CPO functions as lateral branches, seamlessly blending strength with adaptability. Meanwhile, the CRO serves as the sturdy trunk, providing essential support and structure to the entire framework. Finally, CRS acts as foundational soil, offering the necessary support at the base of the tree. Together, these components create a harmonized approach, reflecting Sanyou's integral role in facilitating growth within the biopharmaceutical industry. |
|
|
In the dynamic landscape of drug R&D, Sanyou’s CDO business nurtures the progression of drug development from preclinical candidate molecules (PCC) to Investigational New Drug (IND) application stage. Achieving this milestone for Sanyou enables a seamless transition for customers, allowing them to progress to the next phase in drug development, aptly referred to as “flower blossoms” to represent the realisation of collective efforts.
Sanyou comprehensive services, including cell line construction, small-scale process development, analytical method development, validation, pilot production and release testing, toxicology, stability and more, ensure the smooth advancement of drug R&D. The term "flower blossoms" emphasizes the transformative journey and highlights Sanyou's integral contribution to the realization of innovative biopharmaceutical projects. With seven successful IND approvals since 2020 and involvement in over 30 projects for cell line production and process development, Sanyou establishes a stable foundation for drug R&D. |
|
|
The CPO business is the “lateral branches of a sturdy tree,” blending strength with adaptability. With a distinctive super-trillion innovative antibody drug discovery platform, it facilitates cost-effective, focused research initiatives. This streamlined approach acts as a catalyst, saving valuable time and resources, enabling customers to focus on core R&D processes. As project advance, customers can opt for customized methods. This flexibility mirrors the lateral branches of a tree, branching out in various directions to accommodate the unique growth patterns of each project.
In the collaborative CPO model, customers can co-invest in R&D project costs with Sanyou. Similar to lateral branches supporting a tree trunk, Sanyou offers an essential platform and a dedicated team to share the investment burden. The CPO business also extends its services to include transfer of incubated projects and transfer of technologies. It proactively handles tasks related to "breeding and seedling cultivation", delivering candidate projects at specific R&D stages based on customer requirements. This collaborative synergy guarantees the smooth progression of project, efficiently achieving key milestones. Essentially, the CPO business provides vital support, mitigates R&D risks, and cultivates adaptability in research and development, establishing a dynamic and efficient model. |
|
|
The CRO business functions as the core “tree trunk,” providing essential support and structure throughout the drug R&D process i.e. from pre-clinical candidate to (PCC) to stage-specific services. The PCC service spans from raw material preparation to antibody screening, antibody engineering, animal efficacy screening, and more. Additionally, stage-specific services within CRO break down the PCC into individual stages, offering each as a separate, independent service. This modular approach enhances clarity in investment and output, facilitating the rapid and efficient completion of tasks like drug candidate discovery, drug candidate optimization, in vivo and in vitro validation, and more.
Sanyou’s specialized and dedicated team who are scientifically and technically proficient ensures the smooth progression of each step, meeting project demands effectively. By the end of 2023, Sanyu has achieved noteworthy milestones, successfully delivered over 100 PCC projects and completing more than 300 antibody discovery projects. These achievements underscores Sanyou's strength and extensive experience in the field. Moving forward, the focus is to continue to explore innovative projects, proactively R&D engagement, shortening R&D cycles, reduce risks, and enhancing the overall efficiency. |
|
|
Sanyou CRS serves as a vital foundation, providing essential support to our scientist by granting access to raw materials like reference antibodies, proteins, and cell lines crucial for meeting project demands. Like foundational soil, CRS supplies well-validated, off-the-shelf research tools, benefiting the broader scientific community. With a comprehensive inventory of over 100,000 products, Sanyou ensures swift global delivery to all customers.
Sanyou’s expertise in challenging drug target proteins extends to protein customization, utilization preparation technologies such as virus-like particle (VLP) fusion protein preparation, membrane protein extraction, and overexpression cell line technologies. Over the past year, Sanyou has fulfilled over 60,000 orders for protein customization services in just two years. Looking ahead, Sanyou plans to increase investment to broaden the scope and customer base of protein customization services, actively exploring both emerging and international markets. Additionally, the continuously introduction of new reagent products is on the horizon to meet evolving market demands. |
|
|
| The metaphor of a tree, with its soil, trunk, branches, and blossoming flowers, vividly encapsulates the dynamic and flourishing landscape of biopharmaceuticals in Sanyou's context. It reflects Sanyou's profound understanding and unique insights in the field of drug R&D. This metaphorical tree provides an intuitive understanding of the complex structure and developmental trends within the biopharmaceutical industry, emphasizing Sanyou's pivotal position. Looking ahead, Sanyou is dedicated to upholding core principles in drug research and development. Our ongoing commitment involves expanding and refining our business model to ensure continuous excellence in the field. |
|
|
|
|
|